HeartBeam Provides Update on Regulatory Path Following FDA Decision on 12-Lead ECG Synthesis Software Application ...

HeartBeam (BEAT) announced its regulatory strategy following receipt of a Not Substantially Equivalent, or NSE, decision on the company’s 510(k) ...

A 52-year-old man hospitalized with chest pain is found to have a slow heart rate and evidence of heart block. What does an ...

A 94-year-old female with history of hypertension, chronic kidney disease, and hyperlipidemia presents to the emergency ...

HeartBeam is pursuing several parallel paths to address the FDA’s concerns, including a potential appeal process or resubmission of a 510 (k) application. The company noted that the appeal process ...

ADInstruments Lt educational platform provides pre designed laboratory exercises that incorporate physiological data acquisition, allowing students to perform ECG recordings while learning proper ...

Key points A 56-year-old woman presented to the emergency department with a 2-day history of central chest pain and dyspnea. Her medical history included having had a myocardial infarction (MI) with n ...

Amita Muchhal, the mother of Palash Muchhal, shed insights on her son's and Smriti Mandhana's delayed wedding and her ...

Score big deals for the holidays with discounts on small kitchen appliances, cookware, great tech, and moreWe’re highlighting ...

Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. Although it can present with an ...

HeartBeam shares jumped 40.75% in after-hours trading after the company outlined its regulatory strategy following the FDA's Not Substantially Equivalent decision.

If you’re looking to score the best discounts on Black Friday, we suggest scrolling through these Best Buy deals.